Azura Ophthalmics Named Altschuler as Chair of the Board
7 September 2021 - - Israeli clinical-stage company Azura Ophthalmics Ltd has appointed Steven M. Altschuler, M.D., as chair of its board of directors, the company said.

Dr. Altschuler brings over 20 years of experience building, scaling and healthcare and biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners.

Previously, he co-founded Spark Therapeutics and served as board chair through its progress from private company to IPO and later acquisition by Roche in 2019.

Trained as a pediatric gastroenterologist, Dr. Altschuler formerly held CEO positions at the Children's Hospital of Philadelphia, one of the United States leading children's hospitals, and the University of Miami Health System.

Currently, Dr. Altschuler is the chair of the board of AsclepiX Therapeutics, 89Bio and PlateletBio, serves on the boards of ImVax, Orchard Therapeutics, Affinivax and WW (formerly Weight Watchers International), and is an independent trustee of the Brigham and Women's Physician Organization.

Dr. Altschuler holds a bachelor's degree in mathematics and an M.D. from Case Western Reserve University.

Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the US.

The company is taking a unique approach to ocular surface disease by developing the first ophthalmic keratolytics for the treatment of lid margin diseases such as Meibomian gland dysfunction, Blepharitis and Contact Lens Discomfort.

By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of patients worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.

Azura Ophthalmics has a clinical development pipeline with an initial focus on developing medicines to treat Meibomian gland dysfunction and Contact Lens Discomfort.